Director dealings: Clinigen's Bacon slices off a chunk

Clinigen Group director John Bacon has sold £1.4m of the pharmaceuticals and clinical trial services group.

Bacon sold 200,000 shares at a price of 717p apiece, but still holds 730,767 shares in the company.

He had originally joined the board as a non-executive director last year and received his 0.93m share holding in Clinigen as part consideration when AIM-listed Clinigen acquired his Link Healthcare, a supplier of specialist pharmaceuticals in Australasia.

Since that time, the shares have risen by around £1 to 730p.

At the company's recent annual shareholder meeting, chairman Peter Allen hailed the year to June as marking "the completion of our transformation into the global market leader in the management and supply of both unlicensed and clinical trial medicines".

Adjusted earnings per share were upped 25% and trading for the new financial year was said to remain in line with the board's expectations.

One big change is that chief executive Peter George stepped down after the meeting, with deputy CEO Shaun Chilton taking over to lead a business looking to leverage its "global leadership positions and drive organic growth supported by acquisitions and the revitalisation of products".